Accessibility Menu
 
Intelligent Bio Solutions logo

Intelligent Bio Solutions

(NASDAQ) INBS

Current Price$3.35
Market Cap$5.74M
Since IPO (2020)-100%
5 Year-100%
1 Year-81%
1 Month-36%

Intelligent Bio Solutions Financials at a Glance

Market Cap

$5.74M

Revenue (TTM)

$3.58M

Net Income (TTM)

$11.29M

EPS (TTM)

$-14.93

P/E Ratio

-0.19

Dividend

$0.00

Beta (Volatility)

0.97 (Low)

Price

$3.35

Volume

12,006.842

Open

$3.08

Previous Close

$2.87

Daily Range

$3.00 - $3.39

52-Week Range

$2.86 - $24.90

INBS News

No articles available.

INBS: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Intelligent Bio Solutions

Industry

Healthcare Equipment and Supplies

Employees

55

CEO

Harry Simeonidis

Website

ibs.inc

Headquarters

New York City, NY 10019, US

INBS Financials

Key Financial Metrics (TTM)

Gross Margin

30%

Operating Margin

-3%

Net Income Margin

-3%

Return on Equity

-146%

Return on Capital

-90%

Return on Assets

-64%

Earnings Yield

-5.26%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$5.74M

Shares Outstanding

2.00M

Volume

12.01K

Short Interest

0.00%

Avg. Volume

2.43M

Financials (TTM)

Gross Profit

$1.25M

Operating Income

$10.64M

EBITDA

$9.45M

Operating Cash Flow

$9.68M

Capital Expenditure

$231.84K

Free Cash Flow

$9.91M

Cash & ST Invst.

$1.02M

Total Debt

$281.81K

Intelligent Bio Solutions Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$896.77K

+47.6%

Gross Profit

$177.84K

-20.3%

Gross Margin

19.83%

N/A

Market Cap

$5.74M

N/A

Market Cap/Employee

$114.87K

N/A

Employees

50

N/A

Net Income

$2.68M

-19.0%

EBITDA

$2.40M

-24.0%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Net Cash

$2.71M

-267.9%

Accounts Receivable

$10.36M

+1514.9%

Inventory

$590.25K

-15.8%

Long Term Debt

$3.06M

+20939.8%

Short Term Debt

$395.52K

-35.3%

Return on Assets

-63.98%

N/A

Return on Invested Capital

-89.96%

N/A

Free Cash Flow

$1.64M

+29.9%

Operating Cash Flow

$1.57M

+32.6%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
HSCSHeartSciences Inc.
$2.51+11.06%
PAVMPAVmed Inc.
$10.09+2.96%
BNGOBionano Genomics, Inc.
$1.16+2.21%
MTNBMatinas BioPharma Holdings, Inc.
$0.52-8.31%

Trending Stocks

Symbol / CompanyPricePrice Chg
NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF
$7.66-0.10%
SQQQProShares Trust - ProShares UltraPro Short Qqq
$81.08-0.09%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$12.22+0.10%
QQQInvesco QQQ Trust
$575.30+0.03%

Questions About INBS

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.